Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obstructive sleep apnea
Biotech
Apnimed aspires for up to $160M IPO as sleep apnea launch nears
Apnimed plans to sell 10 million shares at a price between $14 and $16 apiece.
Darren Incorvaia
Jul 27, 2026 11:30am
Apnimed dreams of IPO to fund launch of sleep apnea pill
Jul 12, 2026 12:50pm
ResMed snaps up Noctrix Health in $340M sleep tech deal
Jun 8, 2026 10:47am
Shionogi pays Apnimed $100M for sleep disorder joint venture
Mar 24, 2026 9:20am
FDA clears Resmed AI for personalizing CPAP settings
Dec 8, 2025 11:50am
Nyxoah plans US debut of OSA implant, as rival lobs patent suit
Aug 13, 2025 11:00am
